Prednisone Mylan Pharma 5 mg compresse
Sponsors
Prevail Therapeutics Inc., AstraZeneca AB, Azienda Ospedaliero Universitaria Pisana
Conditions
Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)Metastatic Prostate CancerSystemic Lupus ErythematosusType 1 Gaucher Disease (Peripheral/Non-neuronopathic Manifestations)
Phase 1
An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Subjects with Peripheral Manifestations of Gaucher Disease
SuspendedCTIS2022-500281-10-02
Start: 2023-10-18Target: 6Updated: 2025-09-11
A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA)
Active, not recruitingCTIS2023-508536-64-00
Start: 2022-05-17Target: 50Updated: 2025-04-28
A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
SuspendedCTIS2022-502942-29-01
Start: 2024-08-05Target: 15Updated: 2025-11-26